March Madness — 25% Off — Limited Time
Get All the Market Moving News, Squawk, and Mentorship NOW
get this deal
Deutsch
Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
March Madness — 25% Off — Limited Time
Get All the Market Moving News, Squawk, and Mentorship NOW
get this deal
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Deutsch
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Sports
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Sports
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
CNS Pharma
(NASDAQ:CNSP)
Intraday
$0.392
0.022
[5.95%]
After-Hours
$0.392
0
[0.00%]
Get Report
Watch
Perks
Buy
Compare Brokers
$0.392
0.022
[5.95%]
At close: Mar 28
$0.392
0
[0.00%]
After Hours: 7:30PM EDT
Get Report
Watch
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for CNS Pharma Stock (NASDAQ:CNSP)
CNS Pharma Stock (NASDAQ: CNSP)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Friday, February 09, 2024
Top 5 Health Care Stocks That Are Preparing To Pump In February
Avi Kapoor
-
Feb 9, 2024, 8:35AM
Wednesday, February 07, 2024
12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga Insights
-
Feb 7, 2024, 4:31PM
Tuesday, January 30, 2024
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga Insights
-
Jan 30, 2024, 4:31PM
Why UPS Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Avi Kapoor
-
Jan 30, 2024, 1:18PM
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga Insights
-
Jan 30, 2024, 12:31PM
CNS Pharmaceuticals shares are trading lower after the company announced pricing of a $4 million public offering.
Benzinga Newsdesk
-
Jan 30, 2024, 9:19AM
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga Insights
-
Jan 30, 2024, 8:05AM
Why Super Micro Computer Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket
Avi Kapoor
-
Jan 30, 2024, 7:52AM
CNS Pharmaceuticals Prices $4M Public Offering Of 13,333,334 Common Shares At $0.30/Share
Benzinga Newsdesk
-
Jan 30, 2024, 2:05AM
Monday, January 29, 2024
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga Insights
-
Jan 29, 2024, 4:31PM
Wednesday, January 24, 2024
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga Insights
-
Jan 24, 2024, 8:05AM
Monday, January 22, 2024
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga Insights
-
Jan 22, 2024, 12:31PM
Thursday, January 18, 2024
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga Insights
-
Jan 18, 2024, 4:31PM
Tuesday, January 16, 2024
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga Insights
-
Jan 16, 2024, 4:31PM
Monday, December 18, 2023
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga Insights
-
Dec 18, 2023, 4:31PM
CNS Pharmaceuticals shares are trading lower. The Data Safety Monitoring Board recommended that the company's ongoing trial of Berubicin for the treatment of glioblastoma multiforme continue without any modification.
Benzinga Newsdesk
-
Dec 18, 2023, 1:47PM
CNS Pharmaceuticals Announces Successful Interim Analysis Of Efficacy And Safety Data In Potentially Pivotal Study Of Berubicin; Independent DSMB Recommends Continuing Clinical Trial Of Berubicin Without Modification
Benzinga Newsdesk
-
Dec 18, 2023, 8:39AM
Tuesday, December 05, 2023
How CNS Pharmaceuticals Is Taking A Different Approach To Find A Treatment For Glioblastoma, A Cancer With A Poor Prognosis And No Cure
Faith Ashmore
-
Sponsored
Wednesday, November 22, 2023
CNS Pharmaceuticals shares are trading higher after the company presented updated safety data from its ongoing study evaluating Berubicin in advance of the pre-planned interim analysis of efficacy.
Benzinga Newsdesk
-
Nov 22, 2023, 11:00AM
CNS Pharmaceuticals Presents Updated Safety Data From Ongoing Study Evaluating Berubicin In Advance Of The Pre-Planned Interim Analysis Of Efficacy
Benzinga Newsdesk
-
Nov 22, 2023, 9:09AM
Wednesday, November 15, 2023
CNS Pharmaceuticals To Release Interim Data By The End Of The Year For Potential Glioblastoma Drug Candidate
Faith Ashmore
-
Sponsored
CNS Pharmaceuticals Says The Company's Current Expectation Is That The Cash On Hand And Cash Raised In Oct. Is Sufficient To Fund Our Operations Through The End Of Q4 2023.
Benzinga Newsdesk
-
Nov 15, 2023, 8:21AM
CNS Pharmaceuticals Q3 2023 Net Loss $(4.5)M Down From $(3.4)M YoY, Cash $0.9M
Benzinga Newsdesk
-
Nov 15, 2023, 8:19AM
Monday, October 16, 2023
Why Streamline Health Solutions Shares Are Trading Lower By Over 68%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Lisa Levin
-
Oct 16, 2023, 1:09PM
Friday, October 13, 2023
Glioblastoma Is the Most Aggressive Type Of Brain Cancer, With No Cure – CNS Pharmaceuticals' Innovative Approach To Treatment Could Offer Hope
Faith Ashmore
-
Sponsored
Wednesday, October 11, 2023
CNS Pharmaceuticals' Ongoing Potentially Pivotal Study Of Berubicin For The Treatment Of Glioblastoma Multiforme Continues Rapid Pace Of Enrollment With 229 Patients Enrolled To Date
Benzinga Newsdesk
-
Oct 11, 2023, 8:48AM
Thursday, September 07, 2023
CNS Pharmaceuticals Reaches Milestone With Enrollment Of 200 Patients In Ongoing Potentially Pivotal Study Of Berubicin With The Treatment Of Glioblastoma Multiforme
Benzinga Newsdesk
-
Sep 7, 2023, 8:48AM
Tuesday, August 22, 2023
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga Insights
-
Aug 22, 2023, 1:31PM
Monday, August 21, 2023
Why Super League Gaming Are Trading Lower By Around 46%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Lisa Levin
-
Aug 21, 2023, 2:36PM
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga Insights
-
Aug 21, 2023, 1:31PM
Monday, August 14, 2023
CNS Pharmaceuticals Presents Updated Results From On-Going Potentially Pivotal Study Of Berubicin In Adult Patients With Recurrent GBM After Failure Of Standard First Line Therapy
Happy Mohamed
-
Aug 14, 2023, 9:10AM
Monday, August 07, 2023
CNS Pharma's Lead Drug Candidate Crosses The Blood Brain Barrier - What Does That Mean? Watch the full show here!
Johnny Rice
-
Aug 7, 2023, 10:20AM
Thursday, August 03, 2023
CNS Pharmaceuticals Provides Clinical Trial Update For Ongoing Potentially Pivotal Study With Berubicin For The Treatment Of Glioblastoma Multiforme
Happy Mohamed
-
Aug 3, 2023, 8:07AM
Thursday, July 27, 2023
CNS Pharmaceuticals Announces Acceptance Of Abstract For Poster Presentation At The 2023 SNO/ASCO CNS Cancer Conference
Benzinga Newsdesk
-
Jul 27, 2023, 9:06AM
Friday, June 02, 2023
12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga Insights
-
Jun 2, 2023, 1:31PM
Why Guidewire Software Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Lisa Levin
-
Jun 2, 2023, 1:00PM
Thursday, May 25, 2023
CNS Pharmaceuticals Achieves Over 50% Completion Of Enrollment In Potentially Pivotal Study With Berubicin For The Treatment Of Glioblastoma Multiforme
Benzinga Newsdesk
-
May 25, 2023, 9:12AM
Monday, May 22, 2023
Why ZIM Integrated Shipping Services Shares Are Trading Lower By 14%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Lisa Levin
-
May 22, 2023, 1:20PM
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga Insights
-
May 22, 2023, 9:06AM
Why Immix Biopharma Shares Are Trading Higher By Around 45%; Here Are 20 Stocks Moving Premarket
Lisa Levin
-
May 22, 2023, 8:06AM
Thursday, May 18, 2023
Why Monro Shares Are Trading Lower By 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Lisa Levin
-
May 18, 2023, 1:19PM
Monday, May 15, 2023
CNS Pharmaceuticals Q1 EPS $(2.59) Down From $(2.44) YoY
Benzinga Newsdesk
-
May 15, 2023, 8:43AM
CNS Pharmaceuticals Q1 2023 Net Loss Of $(4.9)M Compared To $(3.2)M YoY; Cash Balance Of $5.1M Sufficient To Fund Operations Into Q4 Of 2023
Benzinga Newsdesk
-
May 15, 2023, 8:41AM
Saturday, May 06, 2023
EXCLUSIVE: Top 10 Most-Searched Tickers On Benzinga Pro In April, Including Tesla, First Republic Bank And Several AI Stocks
Chris Katje
-
May 6, 2023, 2:37PM
Wednesday, May 03, 2023
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga Insights
-
May 3, 2023, 9:06AM
CNS Pharmaceuticals Investigating Potential Naked Short Selling; Retains Shareholder Intelligence Services, LLC
Benzinga Newsdesk
-
May 3, 2023, 8:52AM
Friday, April 21, 2023
12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga Insights
-
Apr 21, 2023, 1:31PM
Why SAP Shares Are Trading Higher By Around 6%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Lisa Levin
-
Apr 21, 2023, 12:40PM
Thursday, April 20, 2023
What's Going With CNS Pharmaceuticals Stock Today
Vandana Singh
-
Apr 20, 2023, 3:08PM
Why Nevro Shares Are Trading Lower By Around 19%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Lisa Levin
-
Apr 20, 2023, 1:33PM
Show more
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch